55697-50-2

Basic information

• Product Name: methyl 2,4,6-tri-O-benzyl-α-D-galactopyranoside
• Synonyms: methyl 2,4,6-tri-O-benzyl-α-D-galactopyranoside
• CAS NO: 55697-50-2
• Molecular Weight: 464.558
• Mol File: 55697-50-2.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: methyl 2,4,6-tri-O-benzyl-α-D-galactopyranoside(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2,4,6-tri-O-benzyl-α-D-galactopyranoside(55697-50-2)
• EPA Substance Registry System: methyl 2,4,6-tri-O-benzyl-α-D-galactopyranoside(55697-50-2)

Safety Data

• Hazardous Substances Data: 55697-50-2(Hazardous Substances Data)

Upstream product

• 129165-07-7 methyl 3-O-allyl-2,4,6-tri-O-benzyl-alpha-D-galactopyranoside 
• 260411-23-2 (2R,3S,4S,5R,6S)-3,5-Bis-benzyloxy-2-benzyloxymethyl-6-methoxy-4-(naphthalen-2-ylmethoxy)-tetrahydro-pyran 
• 100-39-0 benzyl bromide 
• 129165-06-6 methyl 3-O-allyl-α-D-galactopyranoside 
• 139710-11-5 Methyl 3-O-crotyl-α-D-galactopyranoside 
• 81928-95-2 (2S,3R,4S,5S,6R)-3,4-Bis-allyloxy-5-benzyloxy-6-benzyloxymethyl-2-methoxy-tetrahydro-pyran 
• 101758-39-8 (4aR,6S,7R,8S,8aS)-7,8-Bis-allyloxy-6-methoxy-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxine 
• 88819-25-4 2,3-di-O-allyl-α-D-galactopyranoside 
• 100-44-7 benzyl chloride 
• 4288-93-1 methyl 4,6-O-benzylidene-α-D-galactopyranoside 
• 260411-21-0 methyl 3-O-NAP-α-D-galactoside 
• 3396-99-4 methyl α-D-galactopyranoside 
• 160533-90-4 methyl 2,4,6-tri-O-benzyl-3-O-(methylthio)thiocarbonyl-α-D-galactopyranoside 
• 53685-11-3 (2R,3R,4S,5R,6S)-5-Benzyloxy-2-benzyloxymethyl-6-methoxy-tetrahydro-pyran-3,4-diol 

Downstream Products

• 139710-14-8 Methyl 2,4,6-tri-O-benzyl-3-O-(2,3,4-tri-O-acetyl-6-tosyl-α-D-galactopyranosyl)-α-D-galactopyranoside 
• 160533-90-4 methyl 2,4,6-tri-O-benzyl-3-O-(methylthio)thiocarbonyl-α-D-galactopyranoside 
• 160529-95-3 methyl 2,4,6-tri-O-benzyl-α-D-gulopyranoside 
• 1146467-86-8 C₄₈H₅₁N₃O₁₀ 
• 142698-89-3 methyl 2,4,6-tri-O-benzyl-α-D-xylo-hexopyranosid-3-ulose 

Relevant articles and documents

NOVEL GALACTOSIDE INHIBITOR OF GALECTINS

The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

A simple method for the removal of 4-methoxybenzyl group

Removal of 4-methoxybenzyl group from a series of compounds having various protecting groups has been achieved by treatment with 80% acetic acid in water at 80°C for 4 hours.

Synthesis of double-chain bis-sulfone neoglycolipids of the 2''-, 3''-, 4''-, and 6''-deoxyglobotrioses

2-(Trimethylsilyl)ethyl (Me3SiCH2CH2) 2,3,6-tri-O-benzoyl-4-O-(2,3-di-O-benzoyl-6-O-p-methoxybenzyl-β-D-galactopyranosyl-β-D-glucopyranoside was glycosylated with different 2-, 3-, 4-, or 6-"deoxy-D-galactose" derivatives to give the corresponding deoxytr